TrimGen Corporation specializes in advanced molecular testing technologies, particularly focusing on mutation analysis and DNA/RNA extraction methods. Their proprietary Shifted Termination Assay (STA) technology offers a highly sensitive and accurate approach to detect various mutations, utilizing a unique primer extension method that enhances mutation signals significantly. This method allows for the identification of low-level mutations (1-2%) with results delivered in just three hours, making it a rapid alternative to traditional sequencing methods. The STA technology is designed to work with standard capillary sequencers, ensuring compatibility and ease of use in laboratory settings.

In addition to mutation detection, TrimGen has developed the WaxFree™ method for extracting DNA and RNA from formalin-fixed, paraffin-embedded (FFPE) tissues. This innovative approach minimizes the loss of genetic material during extraction by eliminating the traditional bind-wash-elute steps, which often result in significant DNA/RNA loss. The WaxFree method employs a non-toxic reagent for de-paraffinization, making it safer for both operators and the environment. With high recovery rates and the ability to provide excellent results for Next Generation Sequencing (NGS), TrimGen's technologies are widely utilized in clinical tests and research projects globally, enhancing the efficiency and effectiveness of molecular diagnostics.

United States

TrimGen is a precision medicine company that specializes in pharmacogenomics for behavioral health and chronic pain.

TrimGen Corporation

Company Details